Compare TTGT & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTGT | AUTL |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.4M | 407.2M |
| IPO Year | 2024 | 2025 |
| Metric | TTGT | AUTL |
|---|---|---|
| Price | $4.20 | $1.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $10.75 | $8.50 |
| AVG Volume (30 Days) | 583.2K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $4.45 | $80.32 |
| Revenue Next Year | $2.75 | $53.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $3.41 | $1.18 |
| 52 Week High | $9.00 | $2.70 |
| Indicator | TTGT | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 38.91 | 47.18 |
| Support Level | $3.52 | $1.27 |
| Resistance Level | $4.75 | $1.73 |
| Average True Range (ATR) | 0.39 | 0.14 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 0.38 | 32.68 |
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. The company provides marketing and sales services that deliver business impact for enterprise technology companies. It develops editorial content across multiple technology-focused websites and channels to engage audiences researching information technology solutions. The company generates revenue by providing market insight and market access to the technology market, including enterprise technology, artificial intelligence, channel, cybersecurity, media & entertainment, and service providers. Geographically, it derives the majority of revenue from North America.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.